Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181943 | 0.87 | HPGD (0.46) | HPGDRECQLGLACYP2C19L3MBTL1 | |
| SCHEMBL11738306 | 0.81 | CFTR (0.44) | HPGDRECQLGLACYP2C19L3MBTL1 | |
| SCHEMBL3907867 | 0.79 | CYP2C19 (0.61) | HPGDRECQLGLACYP2C19L3MBTL1 | |
| SCHEMBL7578250 | 0.79 | CYP2C19 (0.61) | HPGDRECQLGLACYP2C19L3MBTL1 | |
| SCHEMBL5862933 | 0.79 | HPGD (0.41) | HPGDRECQLGLACYP2C19L3MBTL1 | |
| SCHEMBL7482429 | 0.77 | CYP2C9 (0.44) | HPGDRECQLGLACYP2C19L3MBTL1 | |
| SCHEMBL54346 | 0.77 | HTR2A (0.59) | LMNAHTR2AHRH1POLBTDP1 | |
| SCHEMBL25381630 | 0.76 | HRH1 (0.63) | HPGDRECQLGLACYP2C19L3MBTL1 | |
| SCHEMBL15829149 | 0.76 | HRH1 (0.63) | HPGDRECQLGLACYP2C19L3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL5683105 | 0.74 | HTR2A (0.56) | CYP2C19LMNATSHRHTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119735582-A | Cyclopentane phenylpropyl furan compound AGLATESTATE E, and preparation method and application thereof | 贵州省天然产物研究中心 | 2025-04-01 | — | — | CN | claimed |
| CN-119735582-B | Cyclopentane phenylpropyl furan compound AGLATESTATE E, and preparation method and application thereof | 贵州省天然产物研究中心 | 2025-10-31 | — | — | CN | disclosed |
| CN-119735582-B | Cyclopentane phenylpropyl furan compound AGLATESTATE E, and preparation method and application thereof | 贵州省天然产物研究中心 | 2025-10-31 | — | — | CN | disclosed |
| CN-119735582-A | Cyclopentane phenylpropyl furan compound AGLATESTATE E, and preparation method and application thereof | 贵州省天然产物研究中心 | 2025-04-01 | — | — | CN | disclosed |
| CN-119735582-A | Cyclopentane phenylpropyl furan compound AGLATESTATE E, and preparation method and application thereof | 贵州省天然产物研究中心 | 2025-04-01 | — | — | CN | disclosed |
| CN-119735582-A | Cyclopentane phenylpropyl furan compound AGLATESTATE E, and preparation method and application thereof | 贵州省天然产物研究中心 | 2025-04-01 | — | — | CN | disclosed |
| CN-113512428-A | Liquid crystal composition with negative dielectric anisotropy and application thereof | 北京八亿时空液晶科技股份有限公司 | 2021-10-19 | — | — | CN | disclosed |
| EP-2953950-B1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | UNIV CALIFORNIA (US) | 2021-01-13 | — | — | EP | disclosed |
| US-10851109-B2 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | MITOKININ LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190194207-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ INC (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194207-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, HAGH, PDF | HPGD 1102/4885RECQL 365/4885GLA 853/4885 |
| US-10851109-B2 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | NLN, NME4, COQ8A | HPGD 311/4885RECQL 182/4885GLA 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.